Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aurinia Pharm Ord (NQ: AUPH )

10.31 +1.02 (+10.98%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 24, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 8,338,533
Open 9.220
Bid (Size) 10.31 (1)
Ask (Size) 10.38 (3)
Prev. Close 9.290
Today's Range 9.220 - 10.66
52wk Range 4.070 - 13.41
Shares Outstanding 128,395,927
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Pharmaceuticals's Return On Capital Employed Insights
 
Via Benzinga

Performance

YTD
+73.57%
+73.57%
1 Month
+30.34%
+30.34%
3 Month
+127.59%
+127.59%
6 Month
+46.66%
+46.66%
1 Year
-19.45%
-19.45%

More News

Read More
What's Going On With Aurinia Pharmaceuticals Stock Today?
Via Benzinga
Aurinia Reports Fourth Quarter and Full Year 2022 Financial Results and Company Updates
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Preview: Aurinia Pharmaceuticals's Earnings
Via Benzinga
Why Shares of Aurinia Pharmaceuticals Soared This Week
Via The Motley Fool
What 4 Analyst Ratings Have To Say About Aurinia Pharmaceuticals
Via Benzinga
Aurinia Pharmaceuticals to Present at Upcoming Investor Healthcare Conference
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Pharmaceuticals to Release Fourth Quarter and Full Year Financial and Operational Results on February 28, 2023
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Aurinia Pharmaceuticals Inc.
Via Business Wire
These 2 Healthcare Stocks Have Doubled in 2023
Via MarketBeat
Aurinia Announces PTAB Has Terminated Inter Partes Review
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Pharmaceuticals Announces Allowance of a New and Refined Method of Use Patent for LUPKYNIS® in the Treatment of Lupus Nephritis From the United States Patent and Trademark Office
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Provides Preliminary Unaudited Fourth Quarter and Full-year 2022 Net Revenue Results
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Pharmaceuticals to Present at Upcoming 41st Annual J.P. Morgan Healthcare Conference
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tesla, Amazon, Apple, Aurinia Pharma, Vera Therapeutics: Why These 5 Stocks Are Drawing Investors' Attention Today
Via Benzinga
Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Why Horizon Global Shares Are Trading Higher By Over 340%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Aurinia Announces LUPKYNIS® (voclosporin) Patent Challenge Settlement Reached With Sun Pharmaceuticals
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Announces the Great Britain Marketing Authorization of LUPKYNIS® (voclosporin) for the Treatment of Lupus Nephritis
From Aurinia Pharmaceuticals Inc.
Via Business Wire
What 4 Analyst Ratings Have To Say About Aurinia Pharmaceuticals
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 4, 2022
Via Benzinga
Why Greenhill Shares Climbed Around 25%; Here Are 100 Biggest Movers From Yesterday
Via Benzinga
Why Lincoln National Shares Are Trading Lower By 31%? Here Are 72 Stocks Moving In Thursday's Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.